Role of Machine Learning in Precision Oncology: Applications in Gastrointestinal Cancers

Application of Artificial Intelligence in Prediction of Ki-67 Index in Meningiomas: A Systematic Review and Meta-Analysis

BACKGROUND

The Ki-67 index is a histopathological marker that has been reported to be a crucial factor in the biological behavior and prognosis of meningiomas. Several studies have developed artificial intelligence (AI) models to predict the Ki-67 based on radiomics. In this study, we aimed to perform a systematic review and meta-analysis of AI models that predicted the Ki-67 index in meningioma.

METHODS

Literature records were retrieved on April 27, 2024, using the relevant key terms without filters in PubMed, Embase, Scopus, and Web of Science. Records were screened according to the eligibility criteria, and the data from included studies were extracted. The quality assessment was performed using the Quality Assessment of Diagnostic Accuracy Studies-2 (QUADAS-2) tool. The meta-analysis, sensitivity analysis, and meta-regression were conducted using R software.

RESULTS

Our study included 6 studies. The mean Ki-67 ranged from 2.7 ± 2.97 to 4.8 ± 40.3. Of 6 studies, 5 utilized a machine learning method. The most used AI method was the least absolute shrinkage and selection operator. The area under the curve and accuracy ranged from 0.83 to 0.99 and 0.81 to 0.95, respectively. AI models demonstrated a pooled sensitivity of 87.5% (95% confidence interval [CI]: 75.2%, 94.2%), a specificity of 86.9% (95% CI: 75.8%, 93.4%), and a diagnostic odds ratio of 40.02 (95% CI: 13.5, 156.4). The summary receiver operating characteristic curve indicated an area under the curve of 0.931 for the prediction of Ki-67 index status in intracranial meningiomas.

CONCLUSIONS

AI models have demonstrated promising performance for predicting the Ki-67 index in meningiomas and can optimize the treatment strategy.

Accuracy of machine learning in diagnosing microsatellite instability in gastric cancer: A systematic review and meta-analysis

BACKGROUND

Significant challenges persist in the early identification of microsatellite instability (MSI) within current clinical practice. In recent years, with the growing utilization of machine learning (ML) in the diagnosis and management of gastric cancer (GC), numerous researchers have explored the effectiveness of ML methodologies in detecting MSI. Nevertheless, the predictive value of these approaches still lacks comprehensive evidence. Accordingly, this study was carried out to consolidate the accuracy of ML in the prompt detection of MSI in GC.

METHODS

PubMed, the Cochrane Library, the Web of Science, and Embase were retrieved up to March 20, 2024. The risk of bias in the encompassed studies was evaluated utilizing a risk assessment tool for predictive models. Models were then subjected to subgroup analysis based on the modeling variables.

RESULTS

A total of 12 studies, encompassing 11,912 patients with GC, satisfied the predefined inclusion criteria. ML models established in these studies were primarily based on pathological images, clinical features, and radiomics. The results suggested that in the validation sets, the pathological image-based models had a synthesized c-index of 0.86 [95 % CI (0.83-0.89)], with sensitivity and specificity being 0.86 [95 % CI (0.76-0.92)] and 0.83 [95 % CI (0.78-0.87)], respectively; radiomics feature-based models achieved respective values of 0.87 [95 % CI (0.81-0.92)], 0.77 [95 % CI (0.70-0.83)] and 0.81 [95 % CI (0.74-0.87)]; radiomics feature-based models + clinical feature-based models achieved respective values of 0.87 [95 % CI (0.81-0.93)], 0.78 [95 % CI (0.70-0.84)] and 0.79 [95 % CI (0.69-0.86)].

CONCLUSIONS

ML has demonstrated optimal performance in detecting MSI in GC and could serve as a prospective early adjunctive detection tool for MSI in GC. Future research should contemplate minimally invasive or non-invasive, readily collectible, and efficient predictors to augment the predictive accuracy of ML.

Artificial intelligence: clinical applications and future advancement in gastrointestinal cancers

One of the foremost causes of global healthcare burden is cancer of the gastrointestinal tract. The medical records, lab results, radiographs, endoscopic images, tissue samples, and medical histories of patients with gastrointestinal malignancies provide an enormous amount of medical data. There are encouraging signs that the advent of artificial intelligence could enhance the treatment of gastrointestinal issues with this data. Deep learning algorithms can swiftly and effectively analyze unstructured, high-dimensional data, including texts, images, and waveforms, while advanced machine learning approaches could reveal new insights into disease risk factors and phenotypes. In summary, artificial intelligence has the potential to revolutionize various features of gastrointestinal cancer care, such as early detection, diagnosis, therapy, and prognosis. This paper highlights some of the many potential applications of artificial intelligence in this domain. Additionally, we discuss the present state of the discipline and its potential future developments.

Sub-regional CT Radiomics for the Prediction of Ki-67 Proliferation Index in Gastrointestinal Stromal Tumors: A Multi-center Study

RATIONALE AND OBJECTIVES

The objective was to assess and examine radiomics models derived from contrast-enhanced CT for their predictive capacity using the sub-regional radiomics regarding the Ki-67 proliferation index (PI) in patients with pathologically confirmed gastrointestinal stromal tumors (GIST).

METHODS

In this retrospective study, a total of 412 GIST patients across three institutions (223 from center 1, 106 from center 2, and 83 from center 3) was enrolled. Radiomic features were derived from various sub-regions of the tumor region of interest employing the K-means approach. The Least Absolute Shrinkage and Selection Operator (LASSO) regression was employed to identify features correlated with Ki-67 PI level in GIST patients. A support vector machine (SVM) model was then constructed to predict the high level of Ki-67 (Ki-67 index >8%), drawing on the radiomics features from each sub-region within the training cohort.

RESULTS

After features selection process, 6, 9, 9, 7 features were obtained to construct SVM models based on sub-region 1, 2, 3 and the entire tumor, respectively. Among different models, the model developed by the sub-region 1 achieved an area under the receiver operating characteristic curve (AUC) of 0.880 (95% confidence interval [CI]: 0.830 to 0.919), 0.852 (95% CI: 0.770-0.914), 0.799 (95% CI: 0.697-0.879) in the training, external test set 1, and 2, respectively.

CONCLUSION

The results of the present study suggested that SVM model based on the sub-regional radiomics features had the potential of predicting Ki-67 PI level in patients with GIST.

Hepatoid adenocarcinoma of the stomach: discrimination from conventional gastric adenocarcinoma with a computed tomography-based radiomics nomogram

BACKGROUND

Previous studies found it difficult to differentiate hepatoid adenocarcinoma of the stomach (HAS) from conventional gastric adenocarcinoma (CGA). We aimed to assess the efficacy of a computed tomography (CT)-based radiomics nomogram in identifying HAS.

METHODS

Portal phase CT images were collected from 59 patients with HAS and 122 patients with CGA. HAS and CGA were differentiated through univariate analysis of clinical characteristics, serum biochemical biomarkers, and CT features. The construction of the radiomics signature involved the application of the least absolute shrinkage and selection operator (LASSO) regression model. Multivariable logistic regression analysis was employed to establish the CT-based radiomics nomogram.

RESULTS

The separation of HAS patients from CGA patients relied on the serum alpha-fetoprotein (AFP) level and radiomics signature. The area under the curve (AUC) of AFP was 0.726 [95% confidence interval (CI): 0.639-0.801] in the training cohort and 0.681 (95% CI: 0.541-0.800) in the test cohort, whereas the radiomic signature demonstrated a significantly higher AUC of 0.949 (95% CI: 0.895-0.980) in the training cohort and 0.868 (95% CI: 0.749-0.944) in the test cohort. The nomogram model yielded excellent accuracy for identifying HAS, achieving an AUC of 0.970 (95% CI: 0.923-0.992) in the training cohort and 0.905 (95% CI: 0.796-0.968) in the test cohort.

CONCLUSIONS

Radiomics analysis offers promise for differentiating HAS from CGA, and the CT-based radiomics nomogram is likely to have significant clinical implications on HAS distinction.

An ensemble machine learning model assists in the diagnosis of gastric ectopic pancreas and gastric stromal tumors

OBJECTIVE

To develop an ensemble machine learning (eML) model using multiphase computed tomography (MPCT) for distinguishing between gastric ectopic pancreas (GEP) and gastric stromal tumors (GIST) in lesions < 3 cm.

METHODS

In this study, we retrospectively collected MPCT images from 138 patients between April 2017 and June 2023 across two centers. Cohort 1 comprised 94 patients divided into a training cohort and an internal validation cohort, while the 44 patients from Cohort 2 constituted the external validation cohort. Deep learning (DL) models were constructed based on the lesion region, and radiomics features were extracted to develop radiomics models, which were later integrated into the fusion model. Model performance was assessed through the analysis of the area under the receiver operating characteristic curve (AUROC). The diagnostic efficacy of the optimal model was compared with that of a radiologist. Additionally, the radiologist with the assistance of the eML model provides a secondary diagnosis, to assess the potential clinical value of the model.

RESULTS

After evaluation using an external validation cohort, the radiomics model demonstrated the highest performance in the venous phase, achieving AUROC of 0.87. The DL model showed optimal performance in the non-contrast phase, with AUROC of 0.81. The eML achieved the best performance across all models, with AUROC of 0.90. The use of eML-assisted analysis resulted in a significant improvement in the junior radiologist's accuracy, rising from 0.77 to 0.93 (p < 0.05). However, the senior radiologist's accuracy, while improving from 0.86 to 0.95, did not exhibit a statistically significant difference.

CONCLUSION

eML model based on MPCT can effectively distinguish between GEPs and GISTs < 3 cm.

CRITICAL RELEVANCE STATEMENT

The multiphase CT-based fusion model, incorporating radiomics and DL technology, proves effective in distinguishing between GEP and gastric stromal tumors, serving as a valuable tool to enhance diagnoses and offering references for clinical decision-making.

KEY POINTS

No studies yet differentiated these tumors via radiomics or DL. Radiomics and DL methodologies unveil potentially distinct phenotypes within lesions. Quantitative analysis on CT for GIST and ectopic pancreas. Ensemble learning aids accurate diagnoses, assisting treatment decisions.

Exploring potential circRNA biomarkers for cancers based on double-line heterogeneous graph representation learning

BACKGROUND

Compared with the time-consuming and labor-intensive for biological validation in vitro or in vivo, the computational models can provide high-quality and purposeful candidates in an instant. Existing computational models face limitations in effectively utilizing sparse local structural information for accurate predictions in circRNA-disease associations. This study addresses this challenge with a proposed method, CDA-DGRL (Prediction of CircRNA-Disease Association based on Double-line Graph Representation Learning), which employs a deep learning framework leveraging graph networks and a dual-line representation model integrating graph node features.

METHOD

CDA-DGRL comprises several key steps: initially, the integration of diverse biological information to compute integrated similarities among circRNAs and diseases, leading to the construction of a heterogeneous network specific to circRNA-disease associations. Subsequently, circRNA and disease node features are derived using sparse autoencoders. Thirdly, a graph convolutional neural network is employed to capture the local graph network structure by inputting the circRNA-disease heterogeneous network alongside node features. Fourthly, the utilization of node2vec facilitates depth-first sampling of the circRNA-disease heterogeneous network to grasp the global graph network structure, addressing issues associated with sparse raw data. Finally, the fusion of local and global graph network structures is inputted into an extra trees classifier to identify potential circRNA-disease associations.

RESULTS

The results, obtained through a rigorous five-fold cross-validation on the circR2Disease dataset, demonstrate the superiority of CDA-DGRL with an AUC value of 0.9866 and an AUPR value of 0.9897 compared to existing state-of-the-art models. Notably, the hyper-random tree classifier employed in this model outperforms other machine learning classifiers.

CONCLUSION

Thus, CDA-DGRL stands as a promising methodology for reliably identifying circRNA-disease associations, offering potential avenues to alleviate the necessity for extensive traditional biological experiments. The source code and data for this study are available at https://github.com/zywait/CDA-DGRL .

Discrimination between benign and malignant gallbladder lesions on enhanced CT imaging using radiomics

BACKGROUND

Gallbladder cancer is a rare but aggressive malignancy that is often diagnosed at an advanced stage and is associated with poor outcomes.

PURPOSE

To develop a radiomics model to discriminate between benign and malignant gallbladder lesions using enhanced computed tomography (CT) imaging.

MATERIAL AND METHODS

All patients had a preoperative contrast-enhanced CT scan, which was independently analyzed by two radiologists. Regions of interest were manually delineated on portal venous phase images, and radiomics features were extracted. Feature selection was performed using mRMR and LASSO methods. The patients were randomly divided into training and test groups at a ratio of 7:3. Clinical and radiomics parameters were identified in the training group, three models were constructed, and the models' prediction accuracy and ability were evaluated using AUC and calibration curves.

RESULTS

In the training group, the AUCs of the clinical model and radiomics model were 0.914 and 0.968, and that of the nomogram model was 0.980, respectively. There were statistically significant differences in diagnostic accuracy between nomograms and radiomics features (P <0.05). There was no significant difference in diagnostic accuracy between the nomograms and clinical features (P >0.05) or between the clinical features and radiomics features (P >0.05). In the testing group, the AUC of the clinical model and radiomics model were 0.904 and 0.941, and that of the nomogram model was 0.948, respectively. There was no significant difference in diagnostic accuracy between the three groups (P >0.05).

CONCLUSION

It was suggested that radiomics analysis using enhanced CT imaging can effectively discriminate between benign and malignant gallbladder lesions.

Computed tomography-based radiomics diagnostic approach for differential diagnosis between early- and late-stage pancreatic ductal adenocarcinoma

BACKGROUND

One of the primary reasons for the dismal survival rates in pancreatic ductal adenocarcinoma (PDAC) is that most patients are usually diagnosed at late stages. There is an urgent unmet clinical need to identify and develop diagnostic methods that could precisely detect PDAC at its earliest stages.

AIM

To evaluate the potential value of radiomics analysis in the differentiation of early-stage PDAC from late-stage PDAC.

METHODS

A total of 71 patients with pathologically proved PDAC based on surgical resection who underwent contrast-enhanced computed tomography (CT) within 30 d prior to surgery were included in the study. Tumor staging was performed in accordance with the 8th edition of the American Joint Committee on Cancer staging system. Radiomics features were extracted from the region of interest (ROI) for each patient using Analysis Kit software. The most important and predictive radiomics features were selected using Mann-Whitney U test, univariate logistic regression analysis, and minimum redundancy maximum relevance (MRMR) method. Random forest (RF) method was used to construct the radiomics model, and 10-times leave group out cross-validation (LGOCV) method was used to validate the robustness and reproducibility of the model.

RESULTS

A total of 792 radiomics features (396 from late arterial phase and 396 from portal venous phase) were extracted from the ROI for each patient using Analysis Kit software. Nine most important and predictive features were selected using Mann-Whitney U test, univariate logistic regression analysis, and MRMR method. RF method was used to construct the radiomics model with the nine most predictive radiomics features, which showed a high discriminative ability with 97.7% accuracy, 97.6% sensitivity, 97.8% specificity, 98.4% positive predictive value, and 96.8% negative predictive value. The radiomics model was proved to be robust and reproducible using 10-times LGOCV method with an average area under the curve of 0.75 by the average performance of the 10 newly built models.

CONCLUSION

The radiomics model based on CT could serve as a promising non-invasive method in differential diagnosis between early and late stage PDAC.

Prediction of High-Risk Gastrointestinal Stromal Tumor Recurrence Based on Delta-CT Radiomics Modeling: A 3-Year Follow-up Study After Surgery

Background

Medium- to high-risk classification-gastrointestinal stromal tumors (MH-GIST) have a high recurrence rate and are difficult to treat. This study aims to predict the recurrence of MH-GIST within 3 years after surgery based on clinical data and preoperative Delta-CT Radiomics modeling.

Methods

A retrospective analysis was conducted on clinical imaging data of 242 cases confirmed to have MH-GIST after surgery, including 92 cases of recurrence and 150 cases of normal. The training set and test set were established using a 7:3 ratio and time cutoff point. In the training set, multiple prediction models were established based on clinical data of MH-GIST and the changes in radiomics texture of enhanced computed tomography (CT) at different time periods (Delta-CT radiomics). The area under curve (AUC) values of each model were compared using the Delong test, and the clinical net benefit of the model was tested using decision curve analysis (DCA). Then, the model was externally validated in the test set, and a novel nomogram predicting the recurrence of MH-GIST was finally created.

Results

Univariate analysis confirmed that tumor volume, tumor location, neutrophil-lymphocyte ratio (NLR), platelet lymphocyte ratio (PLR), diabetes, spicy hot pot, CT enhancement mode, and Radscore 1/2 were predictive factors for MH-GIST recurrence (P < .05). The combined model based on these above factors had significantly higher predictive performance (AUC = 0.895, 95% confidence interval [CI] = [0.839-0.937]) than the clinical data model (AUC = 0.735, 95% CI = [0.6 62-0.800]) and radiomics model (AUC = 0.842, 95% CI = [0.779-0.894]). Decision curve analysis also confirmed the higher clinical net benefit of the combined model, and the same results were validated in the test set. The novel nomogram developed based on the combined model helps predict the recurrence of MH-GIST.

Conclusions

The nomogram of clinical and Delta-CT radiomics has important clinical value in predicting the recurrence of MH-GIST, providing reliable data reference for its diagnosis, treatment, and clinical decision-making.

CT-based radiomics analysis to predict local progression of recurrent colorectal liver metastases after microwave ablation

The objective of this study is to establish and validate a radiomics nomogram for prediction of local tumor progression (LTP) after microwave ablation (MWA) for recurrent colorectal liver metastases (CRLM) after hepatic resection. We included 318 consecutive recurrent CRLM patients (216 of training while 102 of validation cohort) with contrast-enhanced computerized tomography images treated with MWA between January 2014 and October 2018. Support vector machine-generated radiomics signature was incorporated together with clinical information to establish a radiomics nomogram. Our constructed radiomics signature including 15 features (first-order intensity statistics features, shape and size-based features, gray level size zone/dependence matrix features) performed well in assessing LTP for both cohorts. With regard to its predictive performance, its C-index was 0.912, compared to the clinical or radiomics models only (c-statistic 0.89 and 0.75, respectively) in the training cohort. In the validation cohort, the radiomics nomogram had better performance (area under the curve = 0.89) compared to the radiomics and clinical models (0.85 and 0.69). According to decision curve analysis, our as-constructed radiomics nomogram showed high clinical utility. As revealed by survival analysis, LTP showed worse progression-free survival (3-year progression-free survival 42.6% vs 78.4%, P < .01). High-risk patients identified using this radiomics signature exhibited worse LTP compared with low-risk patients (3-year LTP 80.2% vs 48.6%, P < .01). A radiomics-based nomogram of pre-ablation computerized tomography imaging may be the precious biomarker model for predicting LTP and personalized risk stratification for recurrent CRLM after hepatic resection treated by MWA.

Methodological quality of radiomic-based prognostic studies in gastric cancer: a cross-sectional study

Background

Machine learning radiomics models are increasingly being used to predict gastric cancer prognoses. However, the methodological quality of these models has not been evaluated. Therefore, this study aimed to evaluate the methodological quality of radiomics studies in predicting the prognosis of gastric cancer, summarize their methodological characteristics and performance.

Methods

The PubMed and Embase databases were searched for radiomics studies used to predict the prognosis of gastric cancer published in last 5 years. The characteristics of the studies and the performance of the models were extracted from the eligible full texts. The methodological quality, reporting completeness and risk of bias of the included studies were evaluated using the RQS, TRIPOD and PROBAST. The discrimination ability scores of the models were also compared.

Results

Out of 283 identified records, 22 studies met the inclusion criteria. The study endpoints included survival time, treatment response, and recurrence, with reported discriminations ranging between 0.610 and 0.878 in the validation dataset. The mean overall RQS value was 15.32 ± 3.20 (range: 9 to 21). The mean adhered items of the 35 item of TRIPOD checklist was 20.45 ± 1.83. The PROBAST showed all included studies were at high risk of bias.

Conclusion

The current methodological quality of gastric cancer radiomics studies is insufficient. Large and reasonable sample, prospective, multicenter and rigorously designed studies are required to improve the quality of radiomics models for gastric cancer prediction.

Study registration

This protocol was prospectively registered in the Open Science Framework Registry (https://osf.io/ja52b).

Machine Learning Techniques for Effective Pathogen Detection Based on Resonant Biosensors

We describe a machine learning (ML) approach to processing the signals collected from a COVID-19 optical-based detector. Multilayer perceptron (MLP) and support vector machine (SVM) were used to process both the raw data and the feature engineering data, and high performance for the qualitative detection of the SARS-CoV-2 virus with concentration down to 1 TCID50/mL was achieved. Valid detection experiments contained 486 negative and 108 positive samples, and control experiments, in which biosensors without antibody functionalization were used to detect SARS-CoV-2, contained 36 negative samples and 732 positive samples. The data distribution patterns of the valid and control detection dataset, based on T-distributed stochastic neighbor embedding (t-SNE), were used to study the distinguishability between positive and negative samples and explain the ML prediction performance. This work demonstrates that ML can be a generalized effective approach to process the signals and the datasets of biosensors dependent on resonant modes as biosensing mechanism.

Dynamic learning for imbalanced data in learning chest X-ray and CT images

Massive annotated datasets are necessary for networks of deep learning. When a topic is being researched for the first time, as in the situation of the viral epidemic, handling it with limited annotated datasets might be difficult. Additionally, the datasets are quite unbalanced in this situation, with limited findings coming from significant instances of the novel illness. We offer a technique that allows a class balancing algorithm to understand and detect lung disease signs from chest X-ray and CT images. Deep learning techniques are used to train and evaluate images, enabling the extraction of basic visual attributes. The training objects' characteristics, instances, categories, and relative data modeling are all represented probabilistically. It is possible to identify a minority category in the classification process by using an imbalance-based sample analyzer. In order to address the imbalance problem, learning samples from the minority class are examined. The Support Vector Machine (SVM) is used to categorize images in clustering. Physicians and medical professionals can use the CNN model to validate their initial assessments of malignant and benign categorization. The proposed technique for class imbalance (3-Phase Dynamic Learning (3PDL)) and parallel CNN model (Hybrid Feature Fusion (HFF)) for multiple modalities achieve a high F1 score of 96.83 and precision is 96.87, its outstanding accuracy and generalization suggest that it may be utilized to create a pathologist's help tool.

Machine-Learning-Based Radiomic Features on Pre-Ablation MRI as Predictors of Pathologic Response in Patients with Hepatocellular Carcinoma Who Underwent Hepatic Transplant

Background: The aim was to investigate the role of pre-ablation tumor radiomics in predicting pathologic treatment response in patients with early-stage hepatocellular carcinoma (HCC) who underwent liver transplant. Methods: Using data collected from 2005–2015, we included adult patients who (1) had a contrast-enhanced MRI within 3 months prior to ablation therapy and (2) underwent liver transplantation. Demographics were obtained for each patient. The treated hepatic tumor volume was manually segmented on the arterial phase T1 MRI images. A vector with 112 radiomic features (shape, first-order, and texture) was extracted from each tumor. Feature selection was employed through minimum redundancy and maximum relevance using a training set. A random forest model was developed based on top radiomic and demographic features. Model performance was evaluated by ROC analysis. SHAP plots were constructed in order to visualize feature importance in model predictions. Results: Ninety-seven patients (117 tumors, 31 (32%) microwave ablation, 66 (68%) radiofrequency ablation) were included. The mean model for end-stage liver disease (MELD) score was 10.5 ± 3. The mean follow-up time was 336.2 ± 179 days. Complete response on pathology review was achieved in 62% of patients at the time of transplant. Incomplete pathologic response was associated with four features: two first-order and two GLRM features using univariate logistic regression analysis (p < 0.05). The random forest model included two radiomic features (diagnostics maximum and first-order maximum) and four clinical features (pre-procedure creatinine, pre-procedure albumin, age, and gender) achieving an AUC of 0.83, a sensitivity of 82%, a specificity of 67%, a PPV of 69%, and an NPV of 80%. Conclusions: Pre-ablation MRI radiomics could act as a valuable imaging biomarker for the prediction of tumor pathologic response in patients with HCC.

Machine Learning of Multi-Modal Tumor Imaging Reveals Trajectories of Response to Precision Treatment

The standard assessment of response to cancer treatments is based on gross tumor characteristics, such as tumor size or glycolysis, which provide very indirect information about the effect of precision treatments on the pharmacological targets of tumors. Several advanced imaging modalities allow for the visualization of targeted tumor hallmarks. Descriptors extracted from these images can help establishing new classifications of precision treatment response. We propose a machine learning (ML) framework to analyze metabolic-anatomical-vascular imaging features from positron emission tomography, ultrafast Doppler, and computed tomography in a mouse model of paraganglioma undergoing anti-angiogenic treatment with sunitinib. Imaging features from the follow-up of sunitinib-treated (n = 8, imaged once-per-week/6-weeks) and sham-treated (n = 8, imaged once-per-week/3-weeks) mice groups were dimensionally reduced and analyzed with hierarchical clustering Analysis (HCA). The classes extracted from HCA were used with 10 ML classifiers to find a generalized tumor stage prediction model, which was validated with an independent dataset of sunitinib-treated mice. HCA provided three stages of treatment response that were validated using the best-performing ML classifier. The Gaussian naive Bayes classifier showed the best performance, with a training accuracy of 98.7 and an average area under curve of 100. Our results show that metabolic-anatomical-vascular markers allow defining treatment response trajectories that reflect the efficacy of an anti-angiogenic drug on the tumor target hallmark.

Early Diagnosis of Pancreatic Cancer: Clinical Premonitions, Timely Precursor Detection and Increased Curative-Intent Surgery

BACKGROUND

The overall poor prognosis in pancreatic cancer is related to late clinical detection. Early diagnosis remains a considerable challenge in pancreatic cancer. Unfortunately, the onset of clinical symptoms in patients usually indicate advanced disease or presence of metastasis.

ANALYSIS AND RESULTS

Currently, there are no designated diagnostic or screening tests for pancreatic cancer in clinical use. Thus, identifying risk groups, preclinical risk factors or surveillance strategies to facilitate early detection is a target for ongoing research. Hereditary genetic syndromes are a obvious, but small group at risk, and warrants close surveillance as suggested by society guidelines. Screening for pancreatic cancer in asymptomatic individuals is currently associated with the risk of false positive tests and, thus, risk of harms that outweigh benefits. The promise of cancer biomarkers and use of 'omics' technology (genomic, transcriptomics, metabolomics etc.) has yet to see a clinical breakthrough. Several proposed biomarker studies for early cancer detection lack external validation or, when externally validated, have shown considerably lower accuracy than in the original data. Biopsies or tissues are often taken at the time of diagnosis in research studies, hence invalidating the value of a time-dependent lag of the biomarker to detect a pre-clinical, asymptomatic yet operable cancer. New technologies will be essential for early diagnosis, with emerging data from image-based radiomics approaches, artificial intelligence and machine learning suggesting avenues for improved detection.

CONCLUSIONS

Early detection may come from analytics of various body fluids (eg 'liquid biopsies' from blood or urine). In this review we present some the technological platforms that are explored for their ability to detect pancreatic cancer, some of which may eventually change the prospects and outcomes of patients with pancreatic cancer.